BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
150.3 EUR
+0.35 (+0.23%)
Overall IDP gets a fundamental rating of 5 out of 10. We evaluated IDP against 81 industry peers in the Biotechnology industry. IDP has an excellent financial health rating, but there are some minor concerns on its profitability. IDP is valued quite cheap, but it does not seem to be growing. With these ratings, IDP could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year IDP was profitable.
In the past year IDP had a positive cash flow from operations.
IDP had positive earnings in each of the past 5 years.
Each year in the past 5 years IDP had a positive operating cash flow.
1.2 Ratios
The Return On Assets of IDP (5.51%) is better than 77.78% of its industry peers.
IDP's Return On Equity of 8.84% is fine compared to the rest of the industry. IDP outperforms 77.78% of its industry peers.
The Return On Invested Capital of IDP (9.70%) is better than 85.19% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IDP is in line with the industry average of 11.80%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
IDP's Profit Margin of 15.98% is amongst the best of the industry. IDP outperforms 81.48% of its industry peers.
In the last couple of years the Profit Margin of IDP has declined.
The Operating Margin of IDP (28.50%) is better than 87.65% of its industry peers.
IDP's Operating Margin has declined in the last couple of years.
The Gross Margin of IDP (75.24%) is better than 65.43% of its industry peers.
In the last couple of years the Gross Margin of IDP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IDP is creating some value.
Compared to 1 year ago, IDP has more shares outstanding
Compared to 5 years ago, IDP has less shares outstanding
IDP has a better debt/assets ratio than last year.
2.2 Solvency
IDP has an Altman-Z score of 3.30. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.30, IDP is doing good in the industry, outperforming 71.60% of the companies in the same industry.
The Debt to FCF ratio of IDP is 2.78, which is a good value as it means it would take IDP, 2.78 years of fcf income to pay off all of its debts.
IDP has a Debt to FCF ratio of 2.78. This is in the better half of the industry: IDP outperforms 79.01% of its industry peers.
A Debt/Equity ratio of 0.35 indicates that IDP is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.35, IDP is in line with its industry, outperforming 53.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.3 |
ROIC/WACC1.17
WACC8.29%
2.3 Liquidity
IDP has a Current Ratio of 2.72. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.72, IDP perfoms like the industry average, outperforming 56.79% of the companies in the same industry.
A Quick Ratio of 2.04 indicates that IDP has no problem at all paying its short term obligations.
IDP has a Quick ratio (2.04) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
IDP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
IDP shows a small growth in Revenue. In the last year, the Revenue has grown by 4.77%.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
IDP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.56% yearly.
Based on estimates for the next years, IDP will show a decrease in Revenue. The Revenue will decrease by -0.63% on average per year.
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.55, the valuation of IDP can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 92.59% of the companies listed in the same industry.
IDP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.60.
The Price/Forward Earnings ratio is 11.42, which indicates a very decent valuation of IDP.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 97.53% of the companies listed in the same industry.
IDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.23, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.55 | ||
| Fwd PE | 11.42 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 88.89% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, IDP is valued cheaper than 93.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.45 | ||
| EV/EBITDA | 7.73 |
4.3 Compensation for Growth
IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
5. Dividend
5.1 Amount
IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IDP (1/2/2026, 7:00:00 PM)
150.3
+0.35 (+0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.4%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap22.05B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts74.29
Price Target155.43 (3.41%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)0.32%
PT rev (3m)6.04%
EPS NQ rev (1m)-1%
EPS NQ rev (3m)-54.88%
EPS NY rev (1m)-1.85%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)0.59%
Revenue NY rev (3m)1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.55 | ||
| Fwd PE | 11.42 | ||
| P/S | 2.57 | ||
| P/FCF | 11.45 | ||
| P/OCF | 10.56 | ||
| P/B | 1.42 | ||
| P/tB | 10.86 | ||
| EV/EBITDA | 7.73 |
EPS(TTM)14.25
EY9.48%
EPS(NY)13.16
Fwd EY8.75%
FCF(TTM)13.13
FCFY8.73%
OCF(TTM)14.23
OCFY9.47%
SpS58.4
BVpS105.63
TBVpS13.84
PEG (NY)N/A
PEG (5Y)N/A
Graham Number184.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.3 |
F-Score5
WACC8.29%
ROIC/WACC1.17
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year6.14%
EBIT Next 3Y0.99%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
What is the valuation status for IDP stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
What is the financial health of BIOGEN INC (IDP.DE) stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.54% in the next year.